CSPC Pharmaceutical Group ( (HK:1093) ) has provided an update.
CSPC Pharmaceutical Group Limited announced that its new Class I bi-functional fusion protein drug, JMT108, has received approval from the U.S. FDA to conduct clinical trials in the United States. This approval, alongside prior approval in China, positions the company to advance its research on the drug’s efficacy against advanced malignant tumors, potentially enhancing its market positioning and offering promising implications for stakeholders.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a Hong Kong-based company operating in the pharmaceutical industry, focusing on the development and production of innovative drugs. The company specializes in bi-functional fusion protein drugs and has a strong market presence in both China and international markets.
YTD Price Performance: -4.92%
Average Trading Volume: 8,088
Technical Sentiment Signal: Strong Buy
Current Market Cap: $8.2B
For an in-depth examination of 1093 stock, go to TipRanks’ Stock Analysis page.